Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsPreferred Shares IssuedProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Valion Bio (TIVC) Shares Outstanding (2021 - 2025)

Valion Bio has reported Shares Outstanding over the past 5 years, most recently at $12000.0 for Q4 2025.

  • For Q4 2025, Shares Outstanding fell 97.85% year-over-year to $12000.0; the TTM value through Dec 2025 reached $12000.0, down 97.85%, while the annual FY2025 figure was $12000.0, 97.85% down from the prior year.
  • Shares Outstanding for Q4 2025 was $2.5 million at Valion Bio, up from $1.7 million in the prior quarter.
  • Over five years, Shares Outstanding peaked at $8.9 million in Q1 2021 and troughed at $5693.0 in Q4 2022.
  • A 5-year average of $1.3 million and a median of $367259.0 in 2024 define the central range for Shares Outstanding.
  • Biggest five-year swings in Shares Outstanding: plummeted 98.92% in 2022 and later soared 1414.9% in 2023.
  • Year by year, Shares Outstanding stood at $97153.0 in 2021, then crashed by 94.14% to $5693.0 in 2022, then surged by 25652.54% to $1.5 million in 2023, then plummeted by 62.01% to $556902.0 in 2024, then crashed by 97.85% to $12000.0 in 2025.
  • Business Quant data shows Shares Outstanding for TIVC at $12000.0 in Q4 2025, $1.7 million in Q3 2025, and $965899.0 in Q2 2025.